Company: Chelsea Therapeutics
Starting stock price: $3.82
Ending stock price: $7.85
Percent Change: 92.41%
Details: Chelsea Therapeutics is developing therapies for a number of inflammatory conditions. In 2007 the company won orphan status for Droxidopa, which treats low blood pressure stemming from Parkinson's or from multiple-system atrophy. The drug already has orphan status in the U.S. and is in Phase III trials. Chelsea also has the drug candidate CH-1504 in Phase II trials for rheumatoid arthritis, psoriasis and inflammatory bowel disease.
Chelsea wins European orphan status. Report
FDA grants Droxidopa orphan drug status. Report